BioCentury
ARTICLE | Clinical News

Abiraterone acetate: Additional Phase I/II data

February 18, 2008 8:00 AM UTC

Additional data from the Phase II portion of the Phase I/II COU-AA-001 trial in 44 evaluable patients showed that daily doses of CB7630 produced PSA declines of >50% and >90% in 27 and 11 patients, re...